Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Michael H. Davidson to Quinolines

This is a "connection" page, showing publications Michael H. Davidson has written about Quinolines.

 
Connection Strength
 
 
 
1.270
 
  1. Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014 Aug 01; 36(8):1211-22.
    View in: PubMed
    Score: 0.514
  2. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006 Nov 07; 48(9):1774-81.
    View in: PubMed
    Score: 0.303
  3. Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther. 2005 Sep; 3(5):789-820.
    View in: PubMed
    Score: 0.279
  4. Davidson MH. Update on CETP inhibition. J Clin Lipidol. 2010 Sep-Oct; 4(5):394-8.
    View in: PubMed
    Score: 0.098
  5. McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006 Nov 07; 48(9):1782-90.
    View in: PubMed
    Score: 0.076
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.